The company is focusing on developing new oncolytic virus therapeutics using the world’s leading TTDR (Transcription and Translation Dual Regulated) oncolytic virus platform. By exploring innovative immunotherapy ideas, Virogin is committed to becoming a world leader in the field of immuno-oncology.

Read More


Viriogin Biotech's founders and core team have more than 20 years of experience in oncolytic virus, oncology research and development, and innovative drug commercialization. Virogin Biotech's current employee roster consists of more than 50 talented individuals, including 11 doctors and postdocs, and 8 masters.

Read More